DIAGNOS Updates on CARA Sales and Regulatory Progress

BROSSARD, Quebec, April 08, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to provide an update to the press release dated January 13, 2026 on the regulatory pathway for the future version of its flagship product CARA, which incorporates eye-related disease detection algorithms, and April 1, 2026 announcement regarding U.S. establishment registration renewal and the continued U.S. commercialization status of the legacy version of CARA.

DIAGNOS, a company specializing in artificial intelligence for medical and regulatory purposes, has recently provided an update about its CARA (Computer-Aided Retinal Analysis) platform. This update focuses on the progress the company has made regarding sales and regulatory activities as it seeks to expand the reach of the CARA technology.

The CARA platform is designed to assist healthcare professionals in the detection and management of diabetic retinopathy and other retinal diseases through advanced imaging analysis. This AI-driven solution aims to improve the accuracy and speed of diagnoses, which is crucial in providing timely interventions for patients suffering from vision-threatening conditions.

In the recent report, DIAGNOS highlighted key achievements in its sales and marketing efforts, noting an increased interest from healthcare providers in integrating AI technologies into their practice. The company revealed that it is in discussions with several hospitals and clinics that are considering implementing the CARA platform in their diagnostic workflows. This surge in interest reflects a growing recognition of the value that AI can bring to the healthcare sector, especially in areas that require rapid and precise analyses.

The regulatory activities surrounding CARA are also moving forward. DIAGNOS has been actively pursuing necessary certifications and approvals that facilitate its market entry in various regions. The company is currently engaged with regulatory bodies to ensure compliance with all applicable medical device regulations, which is an essential step before the product can be widely adopted.

Moreover, DIAGNOS is working on a strategy to enhance the efficacy of CARA through continuous technological advancements. The initiative includes ongoing training of the AI algorithms based on a vast database of retinal images, which aims to refine the system's diagnostic capabilities further. As the platform evolves, it is expected that CARA will deliver even more precise results, thereby boosting confidence among healthcare providers and patients.

As DIAGNOS progresses in these areas, it is optimistic about the future potential of CARA in transforming retinal diagnostics. The integration of AI in medical imaging is seen as a revolutionary step that could lead to enhanced patient outcomes, making timely diagnosis and treatment of retinal diseases more effective. The company remains committed to updating its stakeholders on future developments in sales, regulatory progress, and technological improvements in the CARA platform.